ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP16-17 Contract Renewal Overlapping with Termination Notices for Interpreter Agencies
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 20, 2017
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2701 - 2710 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP20-17 Searching Eligibility and Benefits
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 08, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP68-18 Site of Care Drug Infusion/Injection Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 21, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP61-18 Availity Authorization Training with Live Demo
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 06, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP67-18 Pharmacy Benefit Exclusion for Alferon N (interferon alpha-n3), Cytovene (ganciclovir), Foscarvir (foscarnet), Prevymis (letermovir), Trogarzo (ibalizu,ab-uiyk), Vistide (cidofovir) and Zovirax (actclovir)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 21, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP72-18 Pharmacy Benefit Update - New Drug-Related Step Therapy with Quantity Limit Criteria: Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 21, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP28-17 Notification of Provider Submitted Appeals
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 12, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP60R1-18 Update: Change to Call Center for Transportation for MHCP Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 14, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP62-18 2018 Fall Blue Cross Basic Seminars to Include Availity Portal Training
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 14, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP39-16 Digital Breast Tomosynthesis (DBT) for Routine Breast Cancer Screening
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 15, 2016